Pulmonary Nodules

Author/s: 
Matthew E.J. Callister, Gerard Silvestri
Date Added: 
September 12, 2026
Journal/Publication: 
The New England Journal of Medicine
Publisher: 
Massachusetts Medical Society
Publication Date: 
September 2, 2026
Issue: 
9
Volume: 
395
Pages: 
894-905
Type: 
Meta-analyses, Reviews, and Guidelines
Format: 
Article
DOI (1): 
DOI: 10.1056/NEJMcp2515063

RPR Commentary

RPR Commentary: A review of the evaluation and management of pulmonary nodules. James W. Mold, MD, MPH

Abstract

Pulmonary nodules are classified as solid or subsolid, with subsolid nodules further classified as part-solid or pure ground-glass. Management strategies differ according to the type of nodule. A comparison of current and previous imaging studies, when available, is essential to assess the risk of the nodule being malignant. Solid nodules that have been stable for 2 years are considered to be benign, whereas subsolid nodules require a longer period of stability to be considered benign. Prediction models to stratify the risk of the nodule being malignant can be used to guide the management of solid nodules. Computed tomographic (CT) surveillance is indicated for low-risk nodules; positron-emission tomography–CT, biopsy, or both for intermediate-risk nodules; and surgical resection for selected high-risk nodules. Subsolid nodules are often slower growing than solid nodules but are associated with a higher risk of being malignant, especially if a solid component develops or progressively enlarges. Biopsy methods include transthoracic needle biopsy and navigational bronchoscopy. Optimal overall management balances timely diagnosis in persons who have cancer with the avoidance of unnecessary invasive procedures in persons who have benign disease.

Text Availability

Free full text